Neoadjuvant therapy for hepatocellular carcinoma
10.3760/cma.j.cn115396-20220904-00288
- VernacularTitle:肝细胞肝癌的新辅助治疗
- Author:
Hongxiang CAO
1
;
Ping HUANG
Author Information
1. 重庆医科大学附属第一医院肝胆外科，重庆 400016
- Keywords:
Carcinoma, hepatocellular;
Antineoplastic protocols;
Neoadjuvant therapy;
Research progress
- From:
International Journal of Surgery
2022;49(12):859-864
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence rate and mortality in the world. Surgical resection is the main radical method. However, the high recurrence rate leads to poor prognosis. Neoadjuvant therapy refers to anti-tumor therapy for resectable HCC before surgery to reduce tumor load and postoperative recurrence. Although more and more studies show that neoadjuvant therapy can bring survival benefits to patients with liver cancer. However, the indication, applicable population, treatment mode, treatment cycle and safety of new adjuvant therapy are still controversial. In this review, we will review the above issues, as well as the clinical application and research progress of neoadjuvant in hepatocellular carcinoma.
